- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03407573
Restrictive vs Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur (RESULT-NOF)
The Impact of Restrictive Versus Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Many frail and elderly patients undergo surgery for hip fractures every year. Many of these patients have other health problems including heart disease and anaemia (low haemoglobin or "low blood count") either from chronic illness, from bleeding at the time of their injury or during subsequent surgery. The vast majority (more than 95%) of these patients will go on to have surgery. This surgery is often high risk. Patients with this type of injury may already be frail, may be in hospital for a long time and will need rehabilitation. Many of them will develop complications, including heart attacks and some will die.
Doctors looking after these patients commonly prescribe a blood transfusion around the time of surgery. These patient often have anaemia before surgery an lose more blood during their operations. A benefit of blood transfusion is that it may increase the amount of oxygen the blood can carry. One of the main reasons that doctors prescribe blood around the time of surgery is to prevent heart attacks, which can occur if the heart doesn't receive enough oxygen. Another possible benefit of blood transfusion is that it may help patients get out of bed more quickly after surgery. This is another important aspect of their recovery.
However, blood transfusions can have side effects such as causing heart failure or increasing infections after surgery. These can delay patient recovery too. Although some research has been done in this area, anaesthetists and surgeons are still unsure of when to prescribe blood transfusions to these patients. In particular, uncertainty about how low the blood count should be before a blood transfusion is ordered. Some doctors prescribe blood when the haemoglobin count is less than 9 and some at a lower level of 7. Current guidelines suggest that prescribing at a lower haemoglobin count is better, but there is research which suggests that this level is too low if the patient has a history of heart disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom
- Royal Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Adults aged over 50 years Within 48 hours of admission to hospital with fractured Neck of Femur. Exclusion Criteria: Age <50
- Refusal of consent of patient (or consultee) Patient for palliative care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Restrictive
Restrictive transfused when Hb at or below 70
|
Transfusion of red cells dependent on haemoglobin level.
Either transfused at haemoglobin of 7 or 9.
|
|
Active Comparator: Liberal
Will receive blood transfusion when Hb drops below or equal to 90
|
Transfusion of red cells dependent on haemoglobin level.
Either transfused at haemoglobin of 7 or 9.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myocardial Injury
Time Frame: Upto 60 days
|
Myocardial injury defined as a high sensitivity cardiac Troponin 1 (Troponin) concentration above the upper reference limit [URL] OF 16 ng L and 34 ng L in women and men respectively at any time during the study period.
|
Upto 60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myocardial Infarction
Time Frame: within 30 days of surgery
|
Myocardial Infarction defined per the universal definition within 30 days of surgery or before hospital discharge, whichever occurs first.
|
within 30 days of surgery
|
|
Mortality
Time Frame: upto 60 days following surgery
|
Mortality (30; 60 days from day of surgery).
|
upto 60 days following surgery
|
|
Diagnosis of Major Adverse Cardiac Events
Time Frame: within 30 days or before hospital discharge
|
New diagnosis of MACE within 30 days of surgery or before hospital discharge, whichever occurs first.
|
within 30 days or before hospital discharge
|
|
Acute Kidney Injury
Time Frame: within 30 days of surgery or before discharge from hospital whichever occurs first.
|
New diagnosis of Acute Kidney Injury
|
within 30 days of surgery or before discharge from hospital whichever occurs first.
|
|
Infections
Time Frame: within 30 days of surgery or before hospital discharge, whichever is first.
|
New diagnosis of Infectious Complications
|
within 30 days of surgery or before hospital discharge, whichever is first.
|
|
Delirium
Time Frame: within 30 days of surgery or before hospital discharge, whichever occurs first.
|
New diagnosis of Delirium
|
within 30 days of surgery or before hospital discharge, whichever occurs first.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Troponin
Time Frame: within 7 days of surgery (ngL )
|
Peak troponin concentration
|
within 7 days of surgery (ngL )
|
|
Troponin -Time
Time Frame: within 7 days of surgery
|
Area under a Troponin-Time curve
|
within 7 days of surgery
|
|
Red cells transfused
Time Frame: within7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
Number of units red cells transfused
|
within7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
|
Volume in mls of Red Cells Transfused.
Time Frame: within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
Volume of red blood cells transfused in mls
|
within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
|
Haemoglobin postoperatively
Time Frame: days 1,3,5,7 after surgery
|
Postoperative Hb on postoperative days
|
days 1,3,5,7 after surgery
|
|
Nadir Hb
Time Frame: within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
Nadir Hb
|
within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
|
|
Hospital Admission
Time Frame: from admission to discharge date from hospital upto 60 days.
|
Duration of hospital admission (days)
|
from admission to discharge date from hospital upto 60 days.
|
|
Readmission to hospital
Time Frame: upto 60 days of hospital discharge date
|
Incidence of unplanned hospital readmission within 60 days
|
upto 60 days of hospital discharge date
|
|
Destination
Time Frame: at Discharge from hospital with fractured hip upto 60 days of admission
|
Discharge destination (home, other hospital, nursing home, other)
|
at Discharge from hospital with fractured hip upto 60 days of admission
|
|
Health Related Quality of Life
Time Frame: at 60 days after surgery
|
HRQoL at 60 days (EQ 5D)
|
at 60 days after surgery
|
|
Costs
Time Frame: 60 days post randomisation
|
Secondary care costs during 60 days post-randomisation in Great British Pound
|
60 days post randomisation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr.Mike Gillies, Associate Medical Director
Publications and helpful links
General Publications
- Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.
- Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015 Mar 24;350:h1354. doi: 10.1136/bmj.h1354.
- Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012 Aug;256(2):235-44. doi: 10.1097/SLA.0b013e31825b35d5.
- Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015 Oct;102(11):1314-24. doi: 10.1002/bjs.9861.
- Davenport DL, Bowe EA, Henderson WG, Khuri SF, Mentzer RM Jr. National Surgical Quality Improvement Program (NSQIP) risk factors can be used to validate American Society of Anesthesiologists Physical Status Classification (ASA PS) levels. Ann Surg. 2006 May;243(5):636-41; discussion 641-4. doi: 10.1097/01.sla.0000216508.95556.cc.
- Gillies MA, Ghaffar S, Moppett IK, Docherty AB, Clarke S, Rea N, Stephen J, Keerie C, Ray DC, White TO, MacLullich AMJ, Mills NM, Rowley MR, Murthy K, Pearse RM, Stanworth SJ, Walsh TS. A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). Br J Anaesth. 2021 Jan;126(1):77-86. doi: 10.1016/j.bja.2020.06.048. Epub 2020 Jul 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WKRO-2016-0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruitingSevere Aplastic Anemia | Refractory Aplastic Anemia | Newly Diagnosed Aplastic Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)Netherlands, Germany, Italy, United Kingdom, United States, France
-
China Immunotech (Beijing) Biotechnology Co., Ltd.Not yet recruitingAutoimmune Hemolytic AnemiaChina
-
Peking Union Medical College HospitalNot yet recruiting
-
Chinese PLA General HospitalBeijing Friendship Hospital; Beijing 302 Hospital; The University of Hong Kong-Shenzhen... and other collaboratorsEnrolling by invitationSevere Aplastic Anemia | Severe Aplastic Anemia (SAA) | Severe Aplastic Anemia, RefractoryChina
-
Incyte CorporationTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom, Belgium
-
Chen MiaoNot yet recruiting
Clinical Trials on Administration of Red Cell
-
Arrowhead Regional Medical CenterCompletedTrauma Injury | Trauma Blunt | Vascular TraumaUnited States
-
Ain Shams UniversityRecruitingSickle Cell DiseaseEgypt
-
Mayo ClinicDuke University; Blood Systems Research InstituteCompletedBlood Transfusion ComplicationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedCancer | SurgeryFrance
-
Michelle ZellerCanadian Institutes of Health Research (CIHR)RecruitingSex Differences | Health Services | Cardiovascular | Hematology | Critically Ill Intensive Care Unit Patients | Red Blood Cell TransfusionsCanada
-
University of CincinnatiBiomedical Advanced Research and Development Authority; Cerus CorporationUnknownRed Cell Survival in Healthy VolunteersUnited States
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Hospital, ToulouseEtablissement Français du SangNot yet recruitingSickle Cell DiseaseFrance
-
NHS Blood and TransplantUniversity of York; British Medical Research CouncilTerminatedSickle Cell DiseaseUnited Kingdom
-
Ain Shams UniversityCompletedAtrial Fibrillation New Onset